Journals / Kadın Doğum Dergisi / 2005 / Cilt: 4 - Sayı: 1

Is the increment of mammographic dansity during hormone replacement theraphy reversible?

Hormon replasman tedavisinde mammografik dansite artışı reversibl mıdır?

Pages
703–706
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: We saw that HRT discontinued as short a time as one month regressed the mammographic density and decreased the rate of unnecessary invasive mammarian procedures.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim increased mammographic dansity is often seen on the postmenopausal period caused by frequent use hormone replacement therapy, increased mammographic dansity is a potent risk factor of breast cancer.
📊
Key Findings & Data:And that relation increases the frequency of invasive mammarian procedures.This study is designed whether discontinuation of HRT lowers the mammarian density or not Materials and Methods: Our study involved 20 menopausal patients whom regularly controlled in the polyclinic of menopause of Taksim Education and Resarch Hospital.
💡
Conclusion & Impact:Conclusion: We saw that HRT discontinued as short a time as one month regressed the mammographic density and decreased the rate of unnecessary invasive mammarian procedures.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aim increased mammographic dansity is often seen on the postmenopausal period caused by frequent use hormone replacement therapy, increased mammographic dansity is a potent risk factor of breast cancer. And that relation increases the frequency of invasive mammarian procedures.This study is designed whether discontinuation of HRT lowers the mammarian density or not Materials and Methods: Our study involved 20 menopausal patients whom regularly controlled in the polyclinic of menopause of Taksim Education and Resarch Hospital. Patients were already used HRT and were enrolled to three groups Group 1 used estrogen.estrogen plus progesterone (group 2) and tibolone (group3) All patients had increased mammographic density evaluated with Wolf classification. Results:Then HRT was discontinued for a month. All the groups had shown( %37.5, %60, %50 respectively) a decrease in mammographic density. Conclusion: We saw that HRT discontinued as short a time as one month regressed the mammographic density and decreased the rate of unnecessary invasive mammarian procedures.

Özet

Mammografik dansite artışı daha fazla postmenopozal dönemdeki kadınların hormon replasman tedavisi alması nedeni ile klinisyenlerin sık gördüğü bir durumdur. Aynı zamanda meme kanseri için güçlü bir risk faktörü olması nedeni ile de önemlidir. Bu durum memeye yönelik invazif girişim sıklığını arttırmaktadır. Taksim Eğitim ve Araştırma Hastanesi Kadın Hastalıkları ve Doğum Kliniği Menopoz Polikliniği'nde takip edilen ve HRT sırasında mammografik dansite artışı saptanan 20 hasta çalışmaya dahil edildi. Estrogen, estrogen-progesteron ve tibolon kullanan ve mamografilerinde Wolf klasifikasyonuna göre dansite artışı saptanan hastalar üç gruba ayrıldı. Tedaviye bir ay ara verilerek yapılan değerlendirmede hastaların sırası ile %37.5, %60, %50' sinde mammografik dansite değişik oranlarda azalma gösterdi. Tedaviye bir ay gibi kısa bir süre ara verilip daha sonra yapılan değerlendirmede mammografik dansitenin gerilediği görülerek memeye yönelik gereksiz invazif girişimlerin azaltılabileceğini öngördük.

🔖

Cite This Article

YUMRU, E., AYANOĞLU, Y. T., GÜMÜŞTEKİN, N., BOZKURT, M. (2022). Is the increment of mammographic dansity during hormone replacement theraphy reversible?. Kadın Doğum Dergisi, Cilt: 4 - Sayı: 1, 703–706. https://ajindex.com/articles/569087

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Howe HL, Wingo PA, Thun MJ. Annual report to the nation on the status of cancer 1973 thorugh 1998, featuring cancers with recent increasing trends. J Natl C. 2-Feuer EJ, Wun LM, Boring CC. The lifetime riskof developing breast cancer. JNatl Cancer Inst 1993
  2. Armstrong K, Eisen A, Weber B. Assessing the risk of breast cancer. N Engl J Med 2000
  3. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy
  4. collaborative reanalysisofdatafrom51 epidemiological studies of 52705 women with breast cancer and 1084II without breast cancer. Lancet 1997
  5. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives Collaborative reanalysis of indivudial data on 53297 women with breast cancer and 100239 women without breast cancer from 54 epidemiological studies. Lancet 1996
  6. Pasqualini JR, Chetrite G, Blacker C. Concentrations of estrone, estradioland estrone sulfateand evaluation of sulfatase and aromatase activies in pre- and postmenopausal breast cancer. J Clin Endocrinol Metab. 1996
  7. Boyd NF, Lockwood GA, Byng JW, Tritchler DL, Yaffe MJ. Mammographic densities and breast cancer risk. Cancer Epidemiol Biomark Prev 1998
  8. Nyström L, Rutqvist LE, Wall S. Breast cancer screening with mammography: overview of Swedish randomized trials. Lancet 1993
  9. Lundström E, Wilczek B, von Palffy Z, Soderqvist G, Von Schoutz B. Mammographic breast densitiy during hormone replacement therapy: differences according to treatment. Am J Gynecol 1999
  10. Lundström E, Wilczek B, von Palffy Z, Soderqvist G, von Schoutz B. Mammographic breast density during hormone replacement therapy: effects of continous combination. Unoposed transdermal and low- potency estrogen regimens. Climacteric 2001
  11. Wren BF, Eden JA. Do progestogens reduce the risk of breast cancer? A review of the evidence. Menopause 1996
  12. Magnusson C, Baron JA, CorreiaN, Bergström R, Adami HO, Persson I. Breast cancer risk following long- term oestrogen and oestrogen- progestin replacement therapy. Int J Cancer 1999
  13. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Menopausal estrogen and estrogen progestin replacement therapy and breast cancer risk. J Am Med. Assoc. 2000
  14. Ross RK, Paganini- Hill A, Wan PC, Pike MC, Effect of hormone replacement therapy on breast cancer risk: es